These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25385346)

  • 21. Time Course of Subsequent Shocks After Initial Implantable Cardioverter-Defibrillator Discharge and Implications for Driving Restrictions.
    Merchant FM; Hoskins MH; Benser ME; Roberts G; Bastek AN; Knezevic A; Huang Y; Langberg JJ; Leon AR; El-Chami MF
    JAMA Cardiol; 2016 May; 1(2):181-8. PubMed ID: 27437889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Right Ventricular Pacing Increases Risk of Appropriate Implantable Cardioverter-Defibrillator Shocks Asymmetrically: An Analysis of the ALTITUDE Database.
    Cronin EM; Jones P; Seth MC; Varma N
    Circ Arrhythm Electrophysiol; 2017 Oct; 10(10):. PubMed ID: 29030379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization and financial impact of implantable cardioverter-defibrillator patients without interventions 5 years after implantation.
    Reichlin T; Kühne M; Sticherling C; Osswald S; Schaer B
    QJM; 2011 Oct; 104(10):849-57. PubMed ID: 21624895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of Subcutaneous Implantable Cardioverter Defibrillator Implantation in Patients with End-Stage Renal Disease on Dialysis.
    El-Chami MF; Levy M; Kelli HM; Casey M; Hoskins MH; Goyal A; Langberg JJ; Patel A; Delurgio D; Lloyd MS; Leon AR; Merchant FM
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):900-904. PubMed ID: 25952566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults.
    Bettin M; Larbig R; Rath B; Fischer A; Frommeyer G; Reinke F; Köbe J; Eckardt L
    JACC Clin Electrophysiol; 2017 Dec; 3(13):1499-1506. PubMed ID: 29759830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple shocks after upgrade of an implantable cardioverter-defibrillator to a cardiac resynchronization therapy-defibrillator device.
    Francisco GM; Sharma S; Dougherty AH; Kantharia BK
    Cardiol J; 2009; 16(5):473-6. PubMed ID: 19753529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.
    Olde Nordkamp LR; Wilde AA; Tijssen JG; Knops RE; van Dessel PF; de Groot JR
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):91-100. PubMed ID: 23275262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database.
    MacFadden DR; Crystal E; Krahn AD; Mangat I; Healey JS; Dorian P; Birnie D; Simpson CS; Khaykin Y; Pinter A; Nanthakumar K; Calzavara AJ; Austin PC; Tu JV; Lee DS
    Ann Intern Med; 2012 Feb; 156(3):195-203. PubMed ID: 22312139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deactivation of implantable cardioverter-defibrillators: results of patient surveys.
    Herman D; Stros P; Curila K; Kebza V; Osmancik P
    Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of age (<75 Years versus ≥75 Years) to risk of ventricular tachyarrhythmias and implantable cardioverter defibrillator shocks (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).
    Aktas MK; Goldenberg I; Moss AJ; Huang DT; Kutyifa V; Wang PJ; Brenyo A; McNitt S; Zareba W; Barsheshet A
    Am J Cardiol; 2014 Dec; 114(12):1855-60. PubMed ID: 25438913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fraction.
    Naksuk N; Saab A; Li JM; Florea V; Akkaya M; Anand IS; Benditt DG; Adabag S
    J Card Fail; 2013 Jun; 19(6):426-30. PubMed ID: 23743493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
    Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP
    Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up in patients with presumptive Brugada syndrome treated with implanted defibrillators.
    Steven D; Roberts-Thomson KC; Inada K; Seiler J; Koplan BA; Tedrow UB; Sweeney MO; Epstein LE; Stevenson WG
    J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1115-9. PubMed ID: 21545364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Healthcare Utilization and Expenditures Associated With Appropriate and Inappropriate Implantable Defibrillator Shocks.
    Turakhia MP; Zweibel S; Swain AL; Mollenkopf SA; Reynolds MR
    Circ Cardiovasc Qual Outcomes; 2017 Feb; 10(2):. PubMed ID: 28196927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An unusual case of impossible communication between an ICD and programmer.
    Attanasio P; Wutzler A; Huemer M; Parwani AS; Boldt LH; Haverkamp W; Blaschke F
    J Cardiovasc Electrophysiol; 2015 Feb; 26(2):230. PubMed ID: 25257919
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of defibrillation shock in patients implanted with a subcutaneous defibrillator: a biomarker study.
    D'Onofrio A; Russo V; Bianchi V; Cavallaro C; Leonardi S; De Vivo S; Vecchione F; Rago A; Ammendola E; Tavoletta V; Atripaldi L; Mocavero PE; Nigro G
    Europace; 2018 Sep; 20(FI2):f233-f239. PubMed ID: 29095967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study.
    Bhavnani SP; Pavuluri V; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
    Pacing Clin Electrophysiol; 2013 Jul; 36(7):878-84. PubMed ID: 23614760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
    Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.